Taiwan - Delayed Quote TWD

UnicoCell Biomed Co., Ltd. (6794.TW)

63.90
0.00
(0.00%)
As of 9:58:04 AM GMT+8. Market Open.

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Mr. Yi-Pei Hung General Manager -- -- --
Jui-Yu Liu Chief Internal Auditor -- -- --

UnicoCell Biomed Co., Ltd.

No. 13-20, Minquan East Road
5th Floor Section 6 Neihu District
Taipei, 11494
Taiwan
886 2 2792 2699 https://www.unicocell.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan. It develops ELIXCYTE, which is in Phase 2 clinical trials for the treatment of osteoarthritis and chronic kidney disease. The company offers UnicoVial, a cryotube and drug container for cell therapy products, as well as provides testing services. UnicoCell Biomed Co., Ltd. is based in Taipei, Taiwan.

Corporate Governance

UnicoCell Biomed Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.